Sort by
Refine Your Search
-
relevant for drug discovery analysis pipelines, trial design and operational efficiency. Led by Professor Chris Holmes, and with scientific oversight from Oxford Principal Investigators and GSK scientists
-
and research staff. To help them thrive and achieve their ambitions, we have created a comprehensive range of opportunities and initiatives designed to provide an exceptional launchpad for their future
-
informing the development of more precise immunotherapies. The successful candidate will: • Design and carry out in vivo experiments in preclinical mouse models of autoimmunity • Perform
-
validate new technologies for the diagnosis, prevention, and management of sport injuries, with emphasis on safety rather than performance. You will be responsible for the design, execution and analysis
-
fixed-term for two years in the first instance. You will be working in a small highly motivated inter-disciplinary team working towards a shared goal. You will be responsible for the design and testing
-
. The project involves the design and execution of research projects that find the application of main group molecular compounds and clusters as sustainable catalysts. Find out more about the Mehta research and
-
methods to study human bone marrow models using high content imaging approaches. You will lead in designing and establishing new protocols to the laboratory as well as supporting, mentoring and training
-
biotechnology, design, and engineering across Northumbria, Oxford, and Imperial, as well as start-ups and SME collaborators who are already bringing novel materials to market. Applicants should hold a PhD, or be
-
builds on the expertise of the Fuchter group in the design, synthesis and study of optical materials. Find out more about the Fuchter group’s research at: fuchter group About you Applicants must hold a
-
of their impact on cellular and molecular phenotype of iPSC-derived neurons and glia. The work will involve (i) establishment of cultures of iPSC-derived neuronal and glial cells (ii) design of CRISPRa/i strategies